Related Experiment Video
Updated: May 30, 2026
08:49
Models of Bone Metastasis
Published on: September 4, 2012
Serum bone sialoprotein levels and bone metastases.
Mario Uccello1, Giulia Malaguarnera, Marco Vacante
1Department of Senescence, Urological and Neurological Sciences, University of Catania, Catarina, Italy. uccello@hotmail.it
Journal of Cancer Research and Therapeutics
|July 20, 2011
Summary
Serum bone sialoprotein (BSP) shows promise as a cost-effective marker for detecting bone metastases. Elevated BSP levels can aid in early diagnosis, prognosis, and monitoring of skeletal tumor spread.
Area of Science:
- Oncology
- Biochemistry
- Orthopedics
Background:
- Bone metastasis is common and impacts cancer staging, treatment, and prognosis.
- Current imaging techniques for bone metastases have limitations in accuracy and cost.
- Bone turnover markers offer a potentially cheaper screening method.
Purpose of the Study:
- To review the clinical significance of elevated serum bone sialoprotein (BSP) in patients with bone metastases.
- To summarize the biological and pathological roles of BSP in bone remodeling and metastasis.
Main Methods:
- Literature review of studies on serum BSP levels and bone metastases.
- Analysis of research on BSP's role in bone remodeling and cancer progression.
Main Results:
- Increased serum BSP levels are observed in patients with metastatic bone lesions.
- Serum BSP may serve as an early detection marker for bone metastases.
- BSP shows potential as a prognostic factor and for monitoring treatment.
Conclusions:
- Serum BSP is a valuable biomarker for assessing and managing bone metastases.
- BSP aids in evaluating osteolytic disease and provides prognostic information.
- Monitoring BSP levels can assist in evaluating treatment efficacy.